Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABCL NASDAQ:LNTH NASDAQ:MIRM NASDAQ:RYTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCLAbCellera Biologics$5.67-1.0%$6.02$2.74▼$8.44$1.75B1.147.15 million shs2.87 million shsLNTHLantheus$103.73-0.8%$103.14$47.25▼$111.86$6.81B-0.06901,451 shs640,901 shsMIRMMirum Pharmaceuticals$114.36-0.1%$108.55$50.25▼$130.00$6.98B0.48828,259 shs1.40 million shsRYTMRhythm Pharmaceuticals$102.66-1.3%$98.68$74.50▼$122.20$7.13B1.88751,391 shs470,590 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCLAbCellera Biologics-4.02%-14.99%-0.17%+41.48%+16.46%LNTHLantheus-3.09%+0.28%-1.50%+26.31%+44.61%MIRMMirum Pharmaceuticals-2.20%-5.39%+6.23%+24.50%+119.35%RYTMRhythm Pharmaceuticals-2.47%-5.21%+2.54%+22.02%+18.39%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCLAbCellera Biologics$5.67-1.0%$6.02$2.74▼$8.44$1.75B1.147.15 million shs2.87 million shsLNTHLantheus$103.73-0.8%$103.14$47.25▼$111.86$6.81B-0.06901,451 shs640,901 shsMIRMMirum Pharmaceuticals$114.36-0.1%$108.55$50.25▼$130.00$6.98B0.48828,259 shs1.40 million shsRYTMRhythm Pharmaceuticals$102.66-1.3%$98.68$74.50▼$122.20$7.13B1.88751,391 shs470,590 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCLAbCellera Biologics-4.02%-14.99%-0.17%+41.48%+16.46%LNTHLantheus-3.09%+0.28%-1.50%+26.31%+44.61%MIRMMirum Pharmaceuticals-2.20%-5.39%+6.23%+24.50%+119.35%RYTMRhythm Pharmaceuticals-2.47%-5.21%+2.54%+22.02%+18.39%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCLAbCellera Biologics 2.67Moderate Buy$8.0041.09% UpsideLNTHLantheus 2.73Moderate Buy$110.436.46% UpsideMIRMMirum Pharmaceuticals 2.93Moderate Buy$143.4025.39% UpsideRYTMRhythm Pharmaceuticals 2.76Moderate Buy$138.2934.70% UpsideCurrent Analyst Ratings BreakdownLatest ABCL, RYTM, MIRM, and LNTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026ABCLAbCellera Biologics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026RYTMRhythm Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/16/2026LNTHLantheus Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$115.00 ➝ $125.007/15/2026LNTHLantheus MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform ➝ Market Outperform$115.00 ➝ $120.007/9/2026LNTHLantheus B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$97.00 ➝ $129.007/7/2026RYTMRhythm Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$137.00 ➝ $141.007/7/2026MIRMMirum Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$142.00 ➝ $148.007/7/2026ABCLAbCellera Biologics BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$11.007/2/2026MIRMMirum Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$115.00 ➝ $125.006/29/2026LNTHLantheus Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$115.006/23/2026MIRMMirum Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)(Data available from 7/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCLAbCellera Biologics$75.13M23.05N/AN/A$3.23 per share1.76LNTHLantheus$1.54B4.38$6.33 per share16.38$16.43 per share6.31MIRMMirum Pharmaceuticals$521.31M13.38$0.05 per share2,245.63$6.12 per share18.69RYTMRhythm Pharmaceuticals$189.76M37.07N/AN/A$2.08 per share49.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCLAbCellera Biologics-$146.41M-$0.48N/AN/AN/A-181.75%-14.86%-10.62%8/5/2026 (Confirmed)LNTHLantheus$233.56M$4.1525.0019.28N/A18.05%29.32%15.00%8/5/2026 (Estimated)MIRMMirum Pharmaceuticals-$23.36M-$13.61N/A879.69N/A-140.24%-11.28%-3.84%7/30/2026 (Estimated)RYTMRhythm Pharmaceuticals-$196.54M-$3.13N/AN/AN/A-93.33%-203.25%-44.99%8/4/2026 (Estimated)Latest ABCL, RYTM, MIRM, and LNTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2026Q2 2026ABCLAbCellera Biologics-$0.1186N/AN/AN/A$7.85 millionN/A8/5/2026Q2 2026LNTHLantheus$1.33N/AN/AN/A$362.99 millionN/A8/4/2026Q2 2026RYTMRhythm Pharmaceuticals-$0.82N/AN/AN/A$67.58 millionN/A7/30/2026Q2 2026MIRMMirum Pharmaceuticals-$0.7279N/AN/AN/A$166.03 millionN/A5/11/2026Q1 2026ABCLAbCellera Biologics-$0.22-$0.14+$0.08-$0.14$5.41 million$8.32 million5/7/2026Q1 2026LNTHLantheus$1.25$1.46+$0.21$1.80$354.48 million$377.33 million5/6/2026Q1 2026MIRMMirum Pharmaceuticals-$0.75-$13.43-$12.68-$13.43$148.21 million$159.88 million5/5/2026Q1 2026RYTMRhythm Pharmaceuticals-$0.86-$0.83+$0.03-$0.83$55.78 million$60.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABCLAbCellera BiologicsN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABCLAbCellera BiologicsN/A14.0514.05LNTHLantheus0.472.832.64MIRMMirum Pharmaceuticals1.282.091.99RYTMRhythm PharmaceuticalsN/A4.173.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCLAbCellera Biologics61.42%LNTHLantheus99.06%MIRMMirum PharmaceuticalsN/ARYTMRhythm PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipABCLAbCellera Biologics28.40%LNTHLantheus1.70%MIRMMirum Pharmaceuticals8.32%RYTMRhythm Pharmaceuticals5.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABCLAbCellera Biologics500305.38 million218.65 millionOptionableLNTHLantheus1,19365.11 million64.00 millionOptionableMIRMMirum Pharmaceuticals14060.98 million55.91 millionOptionableRYTMRhythm Pharmaceuticals14068.53 million64.49 millionOptionableABCL, RYTM, MIRM, and LNTH HeadlinesRecent News About These CompaniesRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Average Rating of "Moderate Buy" by BrokeragesJuly 22 at 3:45 AM | americanbankingnews.comKuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law FirmJuly 21 at 5:10 PM | prnewswire.comRhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026July 21 at 8:20 AM | markets.businessinsider.comRhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026July 21 at 8:00 AM | globenewswire.comRhythm Pharmaceuticals, Inc. $RYTM Holdings Lifted by WCM Investment Management LLCJuly 21 at 5:59 AM | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Average Recommendation of "Moderate Buy" by BrokeragesJuly 17, 2026 | marketbeat.comKuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law FirmJuly 16, 2026 | globenewswire.comRhythm’s Setmelanotide Extension Study: What Long-Term Data Could Mean for RYTMJuly 15, 2026 | tipranks.comCandriam S.C.A. Has $40.38 Million Stock Holdings in Rhythm Pharmaceuticals, Inc. $RYTMJuly 11, 2026 | marketbeat.comRhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic ObesityJuly 8, 2026 | globenewswire.comIs Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging Setmelanotide Trial Results?June 30, 2026 | finance.yahoo.comPictet Asset Management Holding SA Purchases 52,383 Shares of Rhythm Pharmaceuticals, Inc. $RYTMJune 30, 2026 | marketbeat.comRhythm Pharmaceuticals Stockholders Back Board, Governance ProposalsJune 25, 2026 | tipranks.comLynn Tetrault Sells 37,000 Shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) StockJune 25, 2026 | insidertrades.comCan Rhythm Pharmaceuticals (RYTM) ’s New Data Help Patients With a Rare Hunger Disorder?June 22, 2026 | insidermonkey.comRhythm Pharmaceuticals, Inc. (RYTM) Discusses Positive Interim Results from Phase 2 Setmelanotide Trial in Prader-Willi Syndrome - SlideshowJune 17, 2026 | seekingalpha.comRhythm Pharmaceuticals, Inc. (RYTM) Discusses Positive Interim Results from Phase 2 Setmelanotide Trial in Prader-Willi Syndrome TranscriptJune 17, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Ionis Pharmaceuticals (IONS) and Rhythm Pharmaceuticals (RYTM)June 16, 2026 | theglobeandmail.comRhythm Pharmaceuticals posts long-term setmelanotide data for obesityJune 16, 2026 | proactiveinvestors.comRhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome ...June 15, 2026 | markets.businessinsider.comThe battle against genetic obesity just sent this biotech stock flyingJune 15, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABCL, RYTM, MIRM, and LNTH Company DescriptionsAbCellera Biologics NASDAQ:ABCL$5.67 -0.06 (-1.05%) Closing price 04:00 PM EasternExtended Trading$5.66 -0.01 (-0.18%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.Lantheus NASDAQ:LNTH$103.73 -0.88 (-0.84%) Closing price 04:00 PM EasternExtended Trading$103.50 -0.23 (-0.22%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Mirum Pharmaceuticals NASDAQ:MIRM$114.36 -0.12 (-0.10%) Closing price 04:00 PM EasternExtended Trading$114.28 -0.08 (-0.07%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.Rhythm Pharmaceuticals NASDAQ:RYTM$102.66 -1.31 (-1.26%) Closing price 04:00 PM EasternExtended Trading$102.75 +0.09 (+0.09%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD’s $5 Billion Anthropic Deal Could Redraw the AI Chip Battle Alphabet Crushed Earnings, But One Number Spooked the Market Premium Retail’s Stress Test Is Separating Winners From Losers GE Vernova Just Sent a Mixed AI Signal to Investors Otis Took Another Guidance Cut—But the Story Isn't Over Philip Morris Trimmed Guidance, But Its Growth Story Looks Unshaken The 2026 Blueprint: 6 Stocks for a Brand New Portfolio Cementing the Sky: Why NVIDIA’s Bet on Nebius Matters Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
